News | Coronavirus (COVID-19) | May 26, 2020

FDA Clears Philips Ultrasound Portfolio to Image COVID-19 Related Lung and Cardiac Complications

Philips’ ultrasound portfolio, including Lumify with Reacts handheld tele-ultrasound solution, provides valuable diagnostic insight for front-line care providers  

The Philips Lumify point-of-care ultrasound (POCUS) system assessing a patient in the emergency room combined with telehealth to enable real-time collaboration with other physicians.

The Philips Lumify point-of-care ultrasound (POCUS) system assessing a patient in the emergency room combined with telehealth to enable real-time collaboration with other physicians.

May 26, 2020  — Philips Healthcare recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market a wide range of its ultrasound solutions for the management of COVID-19 (SARS-CoV-2) related lung and cardiac complications. Handheld and portable ultrasound solutions in particular have become valuable tools for clinicians treating COVID-19 patients due to their imaging capabilities, portability and ease of disinfection. As a result of this regulatory clearance, which is an industry first, Philips can provide detailed, practical guidance to support clinicians using its systems and software for patients affected by COVID-19. The clearance applies to Philips ultrasound systems including the Epiq series, Affiniti series, Lumify, CX50 and Sparq diagnostic ultrasound systems, and to off-cart solutions like QLab Advanced Quantification Software.

Ultrasound has shown value in imaging peripheral lung tissue affected by pneumonia, which  is closely tied to COVID-19 lung complications. As respiratory strain can also lead to cardiac dysfunction, COVID-19 patients are at increased risk for cardiac complications. A cardiac ultrasound exam can help in evaluating the effects that disease progression may have on heart function. By imaging COVID-19 patients at the point of care, such as in the emergency department (ED) or intensive care unit (ICU), clinicians can diagnose and monitor patients without the need to move them around the hospital, helping to reduce the risk of virus transmission to other patients or to healthcare professionals.

“Many healthcare providers have told us that our handheld and portable ultrasound solutions are playing a valuable role in their efforts to combat COVID-19,” said Bich Le, senior vice president and general manager ultrasound at Philips. “With this regulatory clearance we can offer clear guidance to ensure safe and effective use of ultrasound to manage COVID-19-related lung and cardiac complications. At the same time, we are investing significantly to ramp up production globally, including at our ultrasound manufacturing plants in the U.S.”

With its broad portfolio, leadership in areas including cardiac ultrasound and the unique capabilities of the Lumify with Reacts handheld tele-ultrasound solution, Philips is well positioned to support healthcare providers with ultrasound solutions as they combat the pandemic. The Lumify with Reacts point-of-care ultrasound solution, which works in conjunction with a compatible smartphone or tablet, is the world’s first ultra-portable ultrasound device with advanced telehealth capabilities. The Reacts communications platform enables two-way audio-visual calls with live ultrasound streaming, so both parties can simultaneously view the live ultrasound image and probe positioning, while discussing and interacting at the same time. In the context of COVID-19, this solution can help minimize the risk of virus transmission for the medical team.

The new guidance highlights the specific presets, transducers, quantification tools and other capabilities available on Philips’ ultrasound systems that are relevant in assessing and managing COVID-19-related lung and cardiac complications. For example, the Epiq CVx premium cardiology ultrasound system includes automated applications for 2-D assessment of the heart, as well as robust 3-D right ventricle volume and ejection fraction measurements. 

The regulatory clearance includes the following Philips ultrasound systems: Epiq series, Affiniti series, Lumify, CX50, and Sparq diagnostic ultrasound systems and off-cart solutions like QLab Advanced Quantification Software. 

For moor information: www.usa.philips.com/healthcare/medical-specialties/covid-19/ultrasound

Related Content

GE Healthcare introduced its artificial intelligence (AI) automation features on its Voluson Swift ultrasound platform at the 2020 Radiological Society of North America (RSNA) virtual meeting. Features of this system include semi-automated contouring, auto identification of fetal anatomy and positioning on imaging. AI is seeing increasing integration in ultrasound systems from numerous vendors.

GE Healthcare introduced its artificial intelligence (AI) automation features on its Voluson Swift ultrasound platform at the 2020 Radiological Society of North America (RSNA) virtual meeting. Features of this system include semi-automated contouring, auto identification of fetal anatomy and positioning on imaging. AI is seeing increasing integration in ultrasound systems from numerous vendors.

Feature | Ultrasound Imaging | March 04, 2021 | By Dave Fornell, Editor
Recent advances in ultrasound image sy...
A single image of a human brain using a magnetic resonance imaging (MRI) machine. Image courtesy of Dr Leon Kaufman. University Of California, San Francisco

A single image of a human brain using a magnetic resonance imaging (MRI) machine. Image courtesy of Dr Leon Kaufman. University Of California, San Francisco

News | Ultrasound Imaging | March 03, 2021
March 3, 2021 — A type of ultrasound scan can detect
A new study by Rashi Mehta--a researcher with the WVU School of Medicine and Rockefeller Neuroscience Institute--finds that focused ultrasound may induce an immunological healing effect in the brains of Alzheimer's patients.

A new study by Rashi Mehta--a researcher with the WVU School of Medicine and Rockefeller Neuroscience Institute--finds that focused ultrasound may induce an immunological healing effect in the brains of Alzheimer's patients. Image courtesy of Caylie Silveria/West Virginia University

News | Focused Ultrasound Therapy | March 02, 2021
March 2, 2021 — West Virginia University scientists used...
An example of cardiac ultrasound longitudinal strain measurements on the Epsilon EchoInsight software. This can be used to assess cardiotoxicity from chemotherapy agents. 

An example of cardiac ultrasound longitudinal strain measurements on the Epsilon EchoInsight software. This can be used to assess cardiotoxicity from chemotherapy agents. 

News | Cardio-oncology | February 25, 2021
February 25, 2020 — Results of a multi-centre, international, clinical trial co-led by Peter Munk Cardiac Centre (PMC
55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio
News | Artificial Intelligence | February 23, 2021
February 23, 2021 — icometrix, world leader in imaging...
Axial FLAIR MR image shows T2 prolongation in bilateral middle cerebellar peduncles (arrows). Findings were associated with restricted diffusion and areas of T1 hypointense signal without enhancement or abnormal susceptibility. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

Axial FLAIR MR image shows T2 prolongation in bilateral middle cerebellar peduncles (arrows). Findings were associated with restricted diffusion and areas of T1 hypointense signal without enhancement or abnormal susceptibility. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | Coronavirus (COVID-19) | February 22, 2021
February 22, 2021 — According to an...
Insightec plans to expand in Latin America through a partnership with Strattner
News | Focused Ultrasound Therapy | February 16, 2021
February 16, 2021 — Insightec, a global healthcare company focused on creating the next generation of patient care, a
The British Institute of Radiology supports the proposal by AXREM that staff members from private suppliers who work shoulder to shoulder with National Health Service (NHS) staff in high-risk areas in hospitals should be recognised as frontline health and social care staff and prioritised for COVID-19 vaccination accordingly.

Getty Images

News | Coronavirus (COVID-19) | February 12, 2021
February 12, 2021 — The British Institute of Radiology supports the proposal by...